List view / Grid view

The European Medicines Agency (EMA)

 

article

Realising the therapeutic potential of MDMA

16 June 2021 | By

Psychedelic drugs are gaining popularity in the pharmaceutical R&D sector because of their apparent benefits for people suffering with neuropsychiatric disorders - and those which are resistant to existing therapies in particular. In this article, Imperial College London’s Professor David Nutt discusses the evidence underlying the development of psychedelic therapies…